Novel [(N-alkyl-3-indolylmethylene)hydrazono]oxindoles arrest cell cycle and induce cell apoptosis by inhibiting CDK2 and Bcl-2: synthesis, biological evaluation and in silico studies

References

• Schwartz GK. CDK inhibitors: cell cycle arrest versus apoptosis. Cell Cycle 2002;1:113–4.
   Web of Science ®Google Scholar
• Damla Arisan E, Obakan P, Coker-Gurkan A, et al. CDK inhibitors induce mitochondria-mediated apoptosis through the activation of polyamine catabolic pathway in LNCaP, DU145 and PC3 prostate cancer cells. Curr Pharm Des 2014;20:180–8.
   PubMed Web of Science ®Google Scholar
• Cho S-J, Kim Y-J, Surh Y-J, et al. Ibulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells. J Biol Chem 2011;286:19662–71.
   PubMed Web of Science ®Google Scholar
• Damiens E, Baratte B, Marie D, et al. Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene 2001;20:3786–97.
   PubMed Web of Science ®Google Scholar
• Perabo FGE, Frössler C, Landwehrs G, et al. Indirubin-3′-monoxime, a CDK inhibitor induces growth inhibition and apoptosis-independent up-regulation of survivin in transitional cell cancer. Anticancer Res 2006;26:2129–35.
   PubMed Web of Science ®Google Scholar
• Davies TG, Tunnah P, Meijer L, et al. Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure 2001;9:389–97.
   PubMed Web of Science ®Google Scholar
• Jautelat R, Brumby T, Schäfer M, et al. From the insoluble dye indirubin towards highly active, soluble CDK2-inhibitors. ChemBioChem 2005;6:531–40.
   PubMed Web of Science ®Google Scholar
• Yan L, Lai F, Chen X, Xiao Z. Discovery of novel indirubin-3'-monoxime derivatives as potent inhibitors against CDK2 and CDK9 . Bioorg Med Chem Lett 2015;25:2447–51.
   PubMed Web of Science ®Google Scholar
• Ahn M-Y, Kim T-H, Kwon S-M, et al. 5-Nitro-5'-hydroxy-indirubin-3'-oxime (AGM130), an indirubin-3'-oxime derivative, inhibits tumor growth by inducing apoptosis against non-small cell lung cancer in vitro and in vivo. Eur J Pharm Sci 2015;79:122–31.
   PubMed Web of Science ®Google Scholar
• Wood DJ, Korolchuk S, Tatum NJ, et al. Differences in the conformational energy landscape of CDK1 and CDK2 suggest a mechanism for achieving selective CDK inhibition. ‏Cell Chem Biol 2019;26:121–30.
   PubMed Web of Science ®Google Scholar
• Bramson HN, Corona J, Davis ST, et al. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis. J Med Chem 2001;44:4339–58.
   PubMed Web of Science ®Google Scholar
• Attia MI, Eldehna WM, Afifi SA, et al. New hydrazonoindolin-2-ones: Synthesis, exploration of the possible anti-proliferative mechanism of action and encapsulation into PLGA microspheres. PLoS One 2017;12:e0181241.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Al-Wabli RI, Almutairi MS, et al. Synthesis and biological evaluation of certain hydrazonoindolin-2-one derivatives as new potent anti-proliferative agents. J Enzyme Inhib Med Chem 2018;33:867–78.
   PubMed Web of Science ®Google Scholar
• Abdel-Aziz HA, Eldehna WM, Keeton AB, et al. Isatin-benzoazine molecular hybrids as potential antiproliferative agents: Synthesis and in vitro pharmacological profiling. Drug Des Devel Ther 2017;11:2333–46.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Almahli H, Al-Ansary GH, et al. Synthesis and in vitro antiproliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer MDA-MB-231 cells as apoptosis-inducing agents. J Enzym Inhib Med Chem 2017;32:600–13.
   PubMed Web of Science ®Google Scholar
• El-Naggar M, Eldehna WM, Almahli H, et al. Novel thiazolidinone/thiazolo [3, 2-a] benzimidazolone-isatin conjugates as apoptotic anti-proliferative agents towards breast cancer: one-pot synthesis and in vitro biological evaluation. Molecules 2018;23:1420.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Nocentini A, Al-Rashood ST, et al. Tumor-associated carbonic anhydrase isoform IX and XII inhibitory properties of certain isatin-bearing sulfonamides endowed with in vitro anticancer activity towards colon cancer. Bioorg Med Chem 2018;81:425–32.
   Web of Science ®Google Scholar
• Eldehna WM, Abo-Ashour MF, Nocentini A, et al. Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents. Eur J Med Chem 2019;162:147–60.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Fares M, Ibrahim HS, et al. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: synthesis, in vitro biological evaluation and molecular docking. Eur J Med Chem 2015;100:89–97.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Abo-Ashour MF, Ibrahim HS, et al. Novel [(3-indolylmethylene) hydrazono] indolin-2-ones as apoptotic anti-proliferative agents: design, synthesis and in vitro biological evaluation. J Enzym Inhib Med Chem 2018;33:686–700.
   PubMed Web of Science ®Google Scholar
• Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107–12.
   PubMed Web of Science ®Google Scholar
• Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757–66.
   PubMed Web of Science ®Google Scholar
• Boyd MR. Cancer. In: Teicher BA, ed. Drug discovery and development: anticancer drug development guide: preclinical screening, clinical trials and approval, 2nd ed. Totowa, NJ: Humana Press; 2014:41–62.
   Google Scholar
• Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 1995;34:91–109.
   Web of Science ®Google Scholar
• Ibrahim HS, Eldehna WM, Fallacara AL, et al. One-pot synthesis of spiro(indoline-3,4'-pyrazolo[3,4-b]pyridine)-5'-carbonitriles as p53-MDM2 interaction inhibitors. Future Med Chem 2018;10:2771–89.
   PubMed Web of Science ®Google Scholar
• Perez HL, Banfi P, Bertrand J, et al. Schmidt, Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists. Bioorg Med Chem Lett 2012;22:3946–50.
   PubMed Web of Science ®Google Scholar
• Delgado-Soler L, Pinto M, Tanaka-Gil K, Rubio-Martinez J. Molecular determinants of Bim(BH3) peptide binding to pro-survival proteins. J Chem Inf Model 2012;52:2107–18.
   PubMed Web of Science ®Google Scholar
• Czabotar PE, Lee EF, van Delft MF, et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc. Natl. Acad. Sci. U.S.A 2007;104:6217–22.
   PubMed Web of Science ®Google Scholar
• Porter J, Payne A, de Candole B, et al. Whitcombe, tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors. Bioorg Med Chem Lett 2009;19:230–3.
   PubMed Web of Science ®Google Scholar
• Enyedy IJ, Ling Y, Nacro K, et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 2001;44:4313–24.
   PubMed Web of Science ®Google Scholar
• Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677–81.
   PubMed Web of Science ®Google Scholar
• Abo-Ashour MF, Eldehna WM, George RF, et al. Novel indole-thiazolidinone conjugates: design, synthesis and whole-cell phenotypic evaluation as a novel class of antimicrobial agents. Eur J Med Chem 2018;160:49–60.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, El Kerdawy AM, Al-Ansary GHA, et al. Type IIA–Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. Eur J Med Chem 2019;163:37–53.
   PubMed Web of Science ®Google Scholar
• Abou-Seri SM, Eldehna WM, Ali MM, El Ella DA. 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation. Eur J Med Chem 2016;107:165–79.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Hassan GS, Al-Rashood ST, et al. Synthesis and in vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents. J Enzyme Inhib Med Chem 2019;34:322–32.
   PubMed Web of Science ®Google Scholar
• Sabt A, Abdelhafez OM, El-Haggar RS, et al. Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: Synthesis, in vitro biological evaluation, and QSAR studies. J Enzyme Inhib Med Chem 2018;33:1095–107.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, El-Naggar DH, Hamed AR, et al. One-pot three-component synthesis of novel spirooxindoles with potential cytotoxic activity against triple-negative breast cancer MDA-MB-231 cells. J Enzyme Inhib Med Chem 2018;33:309–18.
   PubMed Web of Science ®Google Scholar
• Said MA, Eldehna WM, Nocentini A, et al. Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: design, synthesis, and in vitro biological evaluation. Eur J Med Chem 2020;189:112019.
   PubMed Web of Science ®Google Scholar
• Abo-Ashour MF, Eldehna WM, Nocentini A, et al. 3-Hydrazinoisatin-based benzenesulfonamides as novel carbonic anhydrase inhibitors endowed with anticancer activity: Synthesis, in vitro biological evaluation and in silico insights. Eur J Med Chem 2019;184:111768.
   PubMed Web of Science ®Google Scholar
• Ibrahim HS, Albakri ME, Mahmoud WR, et al. Synthesis and biological evaluation of some novel thiobenzimidazole derivatives as anti-renal cancer agents through inhibition of c-MET kinase. Bioorg Chem 2019;85:337–48.
   PubMed Web of Science ®Google Scholar